An evidence review and gap analysis for obstructive hypertrophic cardiomyopathy
Authors:
Open Access
- 10 August 2024
- journal article
- review article
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 24 (1) , 1-11
Abstract
Patients with obstructive hypertrophic cardiomyopathy (oHCM) have a substantial humanistic, clinical, and economic burden due to the array of symptoms and complications associated with the disease. The objective of this review was to identify key evidence gaps related to oHCM, specifically in Europe, North America, and Japan. A targeted literature review was conducted using PubMed to identify English-language studies published between 2012 and 2022 assessing patients with HCM/oHCM in France, Germany, Italy, Spain, the United Kingdom (UK), the United States (US), Canada, and Japan. Outcomes of interest were epidemiology, natural history, pathophysiology, management, and clinical, economic, and humanistic burden. Identified studies were assessed qualitatively to characterize evidence gaps. Among 2,262 abstracts and 531 full-text articles screened, 178 articles were included from PubMed searches. An additional 16 unique studies were identified via a supplemental Google Scholar search initially conducted in January 2023 and updated in July 2024. Disease natural history, pathophysiology, and management were well documented globally. Significant evidence gaps were noted for the epidemiology, treatment, and burden of oHCM. Although multiple US studies were identified on the clinical, economic, and humanistic burden of oHCM, and one clinical burden study was found for Japan, there was a lack of evidence for France, Germany, Italy, Spain, the UK, and Canada. Major evidentiary gaps exist for the epidemiology, treatment, and burden of oHCM. Future research should address these gaps, with a specific focus on generating real-world evidence for Canada and European countries that will support the evaluation of emerging therapies in these regions.Keywords
Funding Information
- Cytokinetics (n/a, n/a)
This publication has 45 references indexed in Scilit:
- Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal ReductionJAMA Cardiology, 2023
- Ventricular Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy (Analysis Spanning 60 Years Of Practice): AJC Expert PanelThe American Journal of Cardiology, 2022
- Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to BedsideDrugs, 2022
- Treatment Changes, Healthcare Resource Utilization, and Costs Among Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Database StudyCardiology and Therapy, 2022
- Clinical Diagnosis of Hypertrophic Cardiomyopathy Over Time in the United States (A Population-Based Claims Analysis)The American Journal of Cardiology, 2021
- Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New PerspectivesCurrent Heart Failure Reports, 2021
- Prevalence, causes and predictors of cardiovascular hospitalization in patients with hypertrophic cardiomyopathyInternational Journal of Cardiology, 2020
- Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United StatesThe American Journal of Cardiology, 2016
- Misconceptions and Facts About Hypertrophic CardiomyopathyThe American Journal of Medicine, 2016
- Prevalence of hypertrophic cardiomyopathy in an outpatient population referred for echocardiographic studyThe American Journal of Cardiology, 1994